<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H82B61A4CC57648E7B209573A1C0057D2" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 3678 IH: Preserving Access to Orphan Drugs Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-10-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 3678</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20151001">October 1, 2015</action-date>
			<action-desc><sponsor name-id="K000376">Mr. Kelly of Pennsylvania</sponsor> (for himself, <cosponsor name-id="B001273">Mrs. Black</cosponsor>, <cosponsor name-id="N000015">Mr. Neal</cosponsor>, <cosponsor name-id="H001065">Mr. Holding</cosponsor>, <cosponsor name-id="R000053">Mr. Rangel</cosponsor>, <cosponsor name-id="J000290">Ms. Jenkins of Kansas</cosponsor>, <cosponsor name-id="T000462">Mr. Tiberi</cosponsor>, <cosponsor name-id="M001158">Mr. Marchant</cosponsor>, and <cosponsor name-id="N000181">Mr. Nunes</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical
			 manufacturers and importers, and for other purposes.</official-title>
	</form>
	<legis-body id="HDDF6D2DD86834FFCBD718EB41396EAC1" style="OLC">
 <section id="HC4C90BD549854B7EAAC6D75BAE966B46" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Preserving Access to Orphan Drugs Act of 2015</short-title></quote>.</text> </section><section id="H7C6043BB9A754476A833CABB6146BA33" section-type="subsequent-section"><enum>2.</enum><header>Clarification of orphan drug exception to annual fee on branded prescription pharmaceutical manufacturers and importers</header> <subsection commented="no" id="HCA19BE3C3F1C44AEA0214FC255526A5E"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Paragraph (3) of section 9008(e) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/26/4001">26 U.S.C. 4001</external-xref> note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="HFB6683D0659D4D7DAD0F97143FB6D81F" style="OLC">
					<paragraph commented="no" id="HAC9092B2E4C74ECBB5622DFFA8E97AE1"><enum>(3)</enum><header>Exclusion of orphan drug sales</header>
 <subparagraph commented="no" id="H47D7187D6C904C0DA0E20A1E44F2ECDF"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The term <term>branded prescription drug sales</term> shall not include sales of any drug or biological product—</text> <clause commented="no" id="H9318CC1AC4D6436096654B48C05E0526"><enum>(i)</enum><text>with respect to which a credit was allowed for any taxable year under <external-xref legal-doc="usc" parsable-cite="usc/26/45C">section 45C</external-xref> of the Internal Revenue Code of 1986;</text>
 </clause><clause commented="no" id="H476ADC8B95B74DD98C7CB1866909BB57"><enum>(ii)</enum><text>with respect to which a credit was allowable for any taxable year beginning before January 1, 2011, under such section 45C (without regard to whether such credit was claimed or received); or</text>
 </clause><clause commented="no" id="H1D9BD5C0F4F34C038926C9DB88965C69"><enum>(iii)</enum><text display-inline="yes-display-inline">which was any drug or biological product approved or licensed prior to January 1, 2011, by the Food and Drug Administration, for marketing solely for 1 or more rare diseases or conditions.</text>
 </clause></subparagraph><subparagraph commented="no" id="H465FCF8B823C44589405B0F661D7842E"><enum>(B)</enum><header>Expiration</header><text>Subparagraph (A) shall not apply with respect to any drug or biological product after the date on which such drug or biological product is approved or licensed by the Food and Drug Administration for marketing for any indication other than the treatment of a rare disease or condition.</text>
 </subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC086F6CC4D82430BB0DBCED05E189212"><enum>(C)</enum><header>Rare disease or condition</header><text>In this paragraph, the term <term>rare disease or condition</term> has the meaning given such term under <external-xref legal-doc="usc" parsable-cite="usc/26/45C">section 45C(d)(1)</external-xref> of the Internal Revenue Code of 1986.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection commented="no" id="H2BC58E9BED2E4DAFBE29F534FF164092"><enum>(b)</enum><header>Hold harmless for covered entities with no or limited orphan drug sales</header><text>Subsection (b) of section 9008 of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/26/4001">26 U.S.C. 4001</external-xref> note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) is amended by adding at the end the following new paragraph:</text>
				<quoted-block display-inline="no-display-inline" id="H8199D994D4ED4360A765669962D0E3F7" style="OLC">
 <paragraph id="HFB3DA20850DA4EEC941E5884605B1C10"><enum>(5)</enum><header>Adjustment for certain covered entities with no or limited orphan drug sales</header><text>If—</text> <subparagraph id="H0C192D1EA7924A5693173DA32D2CCB8D"><enum>(A)</enum><text>the fee under this section for a calendar year with respect to a covered entity (determined without regard to this paragraph), exceeds</text>
 </subparagraph><subparagraph id="H3AE520B38EB749B58CA2525DA36CB09D"><enum>(B)</enum><text>the fee that would be determined under this section for such year with respect to such entity if branded prescription drug sales of all covered entities were determined without regard to clauses (ii) and (iii) of subsection (e)(3)(A),</text>
						</subparagraph><continuation-text continuation-text-level="paragraph">then such entity's fee under this section for such calendar year shall be determined as described
			 in subparagraph (B).</continuation-text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H536A4E15FB2D4CC5A68F3E832B9183BC"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply with respect to fees the annual payment date for which under section 9008 of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/26/4001">26 U.S.C. 4001</external-xref> note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) is after December 31, 2014.</text>
			</subsection></section></legis-body>
</bill>


